Carl Fredrik Warfvinge

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

Anna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 84 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with¹⁷⁷Lu-DOTATATE

Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge et al. · Journal of Nuclear Medicine · 2021 · 82 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma

Maria Svensson, Carl Fredrik Warfvinge, Richard Fristedt et al. · Oncotarget · 2017 · 62 citations · Full text

Medicine, Immunology, Oncology +15

The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment

Sebastian Lundgren, Carl Fredrik Warfvinge, Jacob Elebro et al. · PLoS ONE · 2016 · 36 citations · Full text

Medicine, Oncology, Pathology +17

Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE

Carl Fredrik Warfvinge, Johan Gustafsson, Daniel Roth et al. · Journal of Nuclear Medicine · 2024 · 34 citations · Full text

Medicine, Nuclear Medicine, Radiology +17